Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels

NEW YORK, Aug. 12, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the launch of a newly formatted website featuring enhanced and readily accessible information for shareholders and other interested parties, improved navigation, and the launch of several online corporate communication channels. The new website can be accessed at www.relmada.com.

"We are very excited about the launch of our new website, which is designed to expand the range of information available while also helping users access the specific information they need faster and easier than ever before.  These advantages are combined with a new sleek and modern design for our site that reflects our company's leadership position in research and innovation," stated Sergio Traversa, CEO of Relmada Therapeutics.  "In addition to our new site, our launch of several new corporate communication channels reflects our company-wide commitment to transparency and dialog with shareholders, clinicians, researchers and others who are interested in our work. We are providing an engaging, mobile-friendly web experience that will help grow our visibility and improve our overall digital presence."

Links to the new Relmada social media platforms are as follows:

Twitter: https://twitter.com/relmada

LinkedIn (company page): https://www.linkedin.com/company/relmada-therapeutics-inc

Facebook: https://www.facebook.com/relmadatherapeutics

Google+: http://plus.google.com/b/105428518607801074584/105428518607801074584/about

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains "forward-looking statements."  These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected.  Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact
Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-376-5776
mbecker@relmada.com

Media Contact:
David Salisbury
Berry & Company Public Relations
Tel: 212-253-8881
dsalisbury@berrypr.com

Logo - https://photos.prnewswire.com/prnh/20150113/168770LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-launch-of-new-website-and-corporate-communication-channels-300127291.html

SOURCE Relmada Therapeutics, Inc.